HK1089450A1 - Method and carrier complexes for delivering molecules to cells - Google Patents

Method and carrier complexes for delivering molecules to cells

Info

Publication number
HK1089450A1
HK1089450A1 HK06109744.4A HK06109744A HK1089450A1 HK 1089450 A1 HK1089450 A1 HK 1089450A1 HK 06109744 A HK06109744 A HK 06109744A HK 1089450 A1 HK1089450 A1 HK 1089450A1
Authority
HK
Hong Kong
Prior art keywords
cells
carrier complexes
delivering molecules
delivering
molecules
Prior art date
Application number
HK06109744.4A
Other languages
English (en)
Inventor
Hazel Szeto
Kesheng Zhao
Alex V Birk
Hugh D Robertson
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Publication of HK1089450A1 publication Critical patent/HK1089450A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
HK06109744.4A 2003-05-01 2006-09-01 Method and carrier complexes for delivering molecules to cells HK1089450A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46751603P 2003-05-01 2003-05-01
PCT/US2004/013772 WO2005001023A2 (fr) 2003-05-01 2004-05-03 Procede et complexes porteurs permettant d'administrer des molecules a des cellules

Publications (1)

Publication Number Publication Date
HK1089450A1 true HK1089450A1 (en) 2006-12-01

Family

ID=33551404

Family Applications (6)

Application Number Title Priority Date Filing Date
HK06109744.4A HK1089450A1 (en) 2003-05-01 2006-09-01 Method and carrier complexes for delivering molecules to cells
HK13113987.3A HK1186482A1 (zh) 2003-05-01 2013-12-17 用於將分子遞送至細胞的方法和載體複合物
HK13113985.5A HK1186406A1 (en) 2003-05-01 2013-12-17 Method and carrier complexes for delivering molecules to cells
HK13113986.4A HK1186407A1 (en) 2003-05-01 2013-12-17 Method and carrier complexes for delivering molecules to cells
HK17105066.9A HK1231424A1 (zh) 2003-05-01 2017-05-19 將分子遞送到細胞的方法和載體複合物
HK18113028.9A HK1253888A1 (zh) 2003-05-01 2018-10-11 將分子遞送到細胞的載體複合物

Family Applications After (5)

Application Number Title Priority Date Filing Date
HK13113987.3A HK1186482A1 (zh) 2003-05-01 2013-12-17 用於將分子遞送至細胞的方法和載體複合物
HK13113985.5A HK1186406A1 (en) 2003-05-01 2013-12-17 Method and carrier complexes for delivering molecules to cells
HK13113986.4A HK1186407A1 (en) 2003-05-01 2013-12-17 Method and carrier complexes for delivering molecules to cells
HK17105066.9A HK1231424A1 (zh) 2003-05-01 2017-05-19 將分子遞送到細胞的方法和載體複合物
HK18113028.9A HK1253888A1 (zh) 2003-05-01 2018-10-11 將分子遞送到細胞的載體複合物

Country Status (18)

Country Link
US (6) US7704954B2 (fr)
EP (7) EP2604285B1 (fr)
JP (6) JP4879020B2 (fr)
KR (1) KR101161823B1 (fr)
CN (2) CN101214380A (fr)
AU (1) AU2004252419B2 (fr)
BR (1) BRPI0409911A (fr)
CA (1) CA2524258C (fr)
DK (4) DK2604621T3 (fr)
ES (3) ES2520815T3 (fr)
HK (6) HK1089450A1 (fr)
MX (1) MXPA05011773A (fr)
NZ (1) NZ543410A (fr)
PL (2) PL2604286T3 (fr)
PT (2) PT2604286E (fr)
SI (1) SI2604285T1 (fr)
WO (1) WO2005001023A2 (fr)
ZA (1) ZA200509229B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030062788A (ko) * 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 ｍｐｈ1-ｂｔｍ 및 이것을포함하는 생명공학제품
ES2436011T3 (es) 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
KR101161823B1 (ko) * 2003-05-01 2012-07-03 코넬 리서치 화운데이션,인크. 세포로 분자를 전달하는 방법 및 이것을 위한 캐리어 복합체
RU2376028C2 (ru) 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
US7534819B2 (en) * 2005-06-10 2009-05-19 University Of Washington Compositions and methods for intracellular delivery of biotinylated cargo
KR20140106761A (ko) * 2005-09-16 2014-09-03 코넬 리서치 화운데이션,인크. Ｃｄ36 발현을 감소시키는 방법
KR20080084937A (ko) * 2005-11-04 2008-09-22 포휴먼텍(주) 융합 폴리펩타이드를 세포로 전달하는 방법
EP2044108A4 (fr) * 2006-07-24 2010-06-30 Forhumantech Co Ltd Composition pharmaceutique pour soulager et traiter des conditions ischémiques et procédé d'administration de cette composition
CN101511872A (zh) * 2006-08-29 2009-08-19 为人技术株式会社 用于抑制凋亡的药物组合物及其递送方法
PL2118123T3 (pl) 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
CA2682174C (fr) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Polypeptides cousus
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
SI2252312T1 (sl) 2008-02-07 2014-08-29 Cornell University, Postopki za preprečevanje ali zdravljenje insulinske rezistence
DK2262520T3 (en) 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
ES2666458T3 (es) * 2008-09-22 2018-05-04 Aileron Therapeutics, Inc. Macrociclos peptidomiméticos
BRPI0920899A2 (pt) 2008-11-24 2016-04-26 Aileron Therapeutics Inc macrociclos peptidomiméticos com propriedades melhoradas
DE102008061044A1 (de) * 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
US20100331265A1 (en) * 2009-03-20 2010-12-30 Tompkins Ronald G Methods for the prevention and treatment of burn injuries and secondary complications
HUE029550T2 (en) * 2009-08-12 2017-03-28 Univ Cornell Methods of preventing or treating metabolic syndrome
EP3318264A1 (fr) 2009-08-24 2018-05-09 Stealth Peptides International, Inc. Procédés et compositions de prévention ou de traitement d'affections ophtalmiques
EP2944317A1 (fr) 2009-10-05 2015-11-18 Cornell University Procédés pour la prévention ou le traitement de l'insuffisance cardiaque
US20110245183A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245182A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
EP3290433A1 (fr) * 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Peptides aromatiques-cationiques et leurs utilisations
CN102010461B (zh) * 2010-10-11 2014-02-12 华南理工大学 一种alpha螺旋状阳离子多肽分子及其制法和应用
GB201018125D0 (en) * 2010-10-26 2010-12-08 Marealis As Peptide
CN107219358A (zh) * 2011-03-24 2017-09-29 康奈尔大学 芳香族阳离子肽及其用途
AU2012271691A1 (en) * 2011-06-14 2014-01-16 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
JP6025311B2 (ja) 2011-08-01 2016-11-16 キヤノン株式会社 眼科診断支援装置および方法
AU2012315586B2 (en) 2011-09-29 2017-07-20 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
AU2012326496B2 (en) * 2011-10-17 2017-08-24 Cornell University Aromatic-cationic peptides and uses of same
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
CN107312066A (zh) * 2011-12-09 2017-11-03 康德生物医疗技术公司 芳香族阳离子肽及其用途
CA2864120A1 (fr) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Macrocycles peptidomimetiques reticules par triazole et par thioether
ES2817877T3 (es) 2012-02-15 2021-04-08 Aileron Therapeutics Inc Macrociclos peptidomiméticos
CN104334181A (zh) * 2012-04-12 2015-02-04 康肽德生物医药技术有限公司 芳香族阳离子肽及其用途
AU2013296494B2 (en) * 2012-08-02 2018-04-26 Stealth Biotherapeutics Inc. Methods for treatment of atherosclerosis
WO2014138429A2 (fr) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leur utilisation dans la régulation de hif1alpha
US9850278B2 (en) 2013-04-25 2017-12-26 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
WO2015134096A1 (fr) * 2014-03-03 2015-09-11 Stealth Peptides International, Inc. Peptides aromatiques-cationiques d'intérêt pharmaceutique
CA2950410A1 (fr) * 2014-05-28 2015-12-03 D. Travis Wilson Compositions therapeutiques comprenant de petites molecules therapeutiques et leurs utilisations
US10576124B2 (en) 2014-05-28 2020-03-03 Stealth Biotherapeutics Corp Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
HUE054626T2 (hu) * 2014-06-25 2021-09-28 Flamma Spa Eljárás D-arginil-2,6-dimetil-L-tirozil-L-lizil-L-fenilalaninamid elõállítására
ES2890676T3 (es) * 2014-06-30 2022-01-21 Flamma Spa Procedimiento para la producción de D-arginil-2,6-dimetil-L-tirosil-L-lisil-L-fenilalaninamida
WO2016004093A2 (fr) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Compositions thérapeutiques comprenant des inhibiteurs de la galectine-3 et utilisations de celles-ci
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
US20160228491A1 (en) * 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
WO2016154058A1 (fr) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leurs utilisations
WO2016209261A1 (fr) * 2015-06-26 2016-12-29 Stealth Biotherapeutics Corp Compositions thérapeutiques comprenant des conjugués de gramicidine s peptidyl ou des acides gras à substitution imidazole, variants associés, et utilisations de ces compositions
EP3347372A4 (fr) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques en tant que modulateurs de mcl-1
CN113876600B (zh) * 2015-10-21 2024-05-17 密歇根大学董事会 用纳米粒检测和治疗龋和微腔
US20200308220A1 (en) * 2015-11-30 2020-10-01 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
EP3542822A4 (fr) 2016-11-16 2020-08-19 Luca Science Inc. Procédé de production de cellule souche myocardique utilisée pour le traitement et/ou la prévention d'un arrêt cardiaque
EP3563833B1 (fr) * 2016-12-28 2024-06-26 Chugai Seiyaku Kabushiki Kaisha Formulation médicamenteuse auto-émulsifiante visant à améliorer le passage transmembranaire de composés
CN107230021B (zh) * 2017-06-08 2020-05-26 桂林理工大学 筛选供水管网泄漏区域的方法
EP3813883A1 (fr) * 2018-06-29 2021-05-05 Glykos Biomedical Oy Conjugués
WO2021132735A2 (fr) 2019-12-27 2021-07-01 Luca Science Inc. Mitochondries isolées ayant une taille plus petite et vésicules à base de membrane lipidique encapsulant les mitochondries isolées
WO2021216499A1 (fr) * 2020-04-23 2021-10-28 North Carolina State University Conjugués peptide-microarn pénétrant dans des cellules pour l'administration intracellulaire de cellules
KR20240073137A (ko) 2020-09-09 2024-05-24 소셜 프로핏 네트워크 미토콘드리아에 비오틴의 전달을 위한 방법 및 조성물

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55500053A (fr) * 1978-01-16 1980-01-31
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ATE136905T1 (de) * 1988-06-30 1996-05-15 Astra Ab Dermorphin-analoge, deren herstellungsverfahren, pharmazeutische zusammensetzungen und methode zur therapeutischen behandlung unter verwendung der analoge
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
NL9001639A (nl) 1990-07-19 1992-02-17 Amc Amsterdam Pt-houdende verbinding, werkwijze voor de bereiding ervan, alsmede toepassing van dergelijke verbindingen.
US5714327A (en) 1990-07-19 1998-02-03 Kreatech Diagnostics Platinum-containing compounds, methods for their preparation and applications thereof
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
EP0747092B1 (fr) * 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrice pour iontophorèse
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2314267A1 (fr) 1997-12-10 1999-06-17 Washington University Systeme anti-pathogene et procedes d'utilisation
WO1999055321A1 (fr) * 1998-04-24 1999-11-04 Mitokor Composes et methodes de traitement de maladies liees aux mitochondries
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
EP1218544B1 (fr) * 1999-10-04 2009-06-03 The University of Medicine and Dentistry of New Jersey Peptides de fixation de'l élément d'ARN TAR
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
GB0005703D0 (en) * 2000-03-09 2000-05-03 Alpharma As Compounds
EP1303186B1 (fr) * 2000-07-18 2011-01-26 Cornell Research Foundation, Inc. Utilisations medicales d'agonistes vis-a-vis de recepteur mu-opioide
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
GB0026924D0 (en) * 2000-11-03 2000-12-20 Univ Cambridge Tech Antibacterial agents
CA2437983C (fr) * 2001-02-16 2011-10-25 Cellgate, Inc. Transporteurs comportant des fractions d'arginine espacees
DE10121982B4 (de) * 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
ES2436011T3 (es) * 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
KR101161823B1 (ko) * 2003-05-01 2012-07-03 코넬 리서치 화운데이션,인크. 세포로 분자를 전달하는 방법 및 이것을 위한 캐리어 복합체
WO2005032481A2 (fr) * 2003-09-30 2005-04-14 Scios Inc. Dérivés de quinazoline en tant que médicaments
RU2376028C2 (ru) 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
KR20140106761A (ko) * 2005-09-16 2014-09-03 코넬 리서치 화운데이션,인크. Ｃｄ36 발현을 감소시키는 방법
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
SI2252312T1 (sl) * 2008-02-07 2014-08-29 Cornell University, Postopki za preprečevanje ali zdravljenje insulinske rezistence
DK2262520T3 (en) * 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
CN112639591A (zh) 2018-06-29 2021-04-09 瑞尔D斯帕克有限责任公司 隐私显示的稳定化

Also Published As

Publication number Publication date
US20100204448A1 (en) 2010-08-12
JP2011168603A (ja) 2011-09-01
US20200299415A1 (en) 2020-09-24
HK1186406A1 (en) 2014-03-14
JP2018158951A (ja) 2018-10-11
EP3167935A1 (fr) 2017-05-17
CN1780851A (zh) 2006-05-31
AU2004252419B2 (en) 2010-02-18
JP5995930B2 (ja) 2016-09-21
DK2604285T3 (en) 2014-12-01
US11845807B2 (en) 2023-12-19
US20130085259A1 (en) 2013-04-04
EP2604286A1 (fr) 2013-06-19
BRPI0409911A (pt) 2006-04-25
EP3167935B1 (fr) 2018-07-18
JP4879020B2 (ja) 2012-02-15
EP2604287A2 (fr) 2013-06-19
US9315586B2 (en) 2016-04-19
EP2604621A1 (fr) 2013-06-19
HK1231424A1 (zh) 2017-12-22
US7704954B2 (en) 2010-04-27
EP3381515B1 (fr) 2020-07-08
HK1186482A1 (zh) 2014-03-14
JP2020105184A (ja) 2020-07-09
ES2520816T3 (es) 2014-11-11
WO2005001023A2 (fr) 2005-01-06
CN100506841C (zh) 2009-07-01
EP2604287A3 (fr) 2014-04-16
EP2604286B1 (fr) 2014-08-27
SI2604285T1 (sl) 2014-12-31
JP2014221846A (ja) 2014-11-27
JP6395749B2 (ja) 2018-09-26
CA2524258C (fr) 2012-08-07
AU2004252419A1 (en) 2005-01-06
US11180574B2 (en) 2021-11-23
NZ543410A (en) 2008-07-31
PL2604285T3 (pl) 2015-02-27
HK1253888A1 (zh) 2019-07-05
MXPA05011773A (es) 2006-02-17
CN101214380A (zh) 2008-07-09
PT2604286E (pt) 2014-11-28
CA2524258A1 (fr) 2005-01-06
EP1625149A4 (fr) 2010-10-06
PL2604286T3 (pl) 2015-03-31
US20170035899A1 (en) 2017-02-09
US10584182B2 (en) 2020-03-10
US20050158373A1 (en) 2005-07-21
HK1186407A1 (en) 2014-03-14
JP2007503461A (ja) 2007-02-22
EP2604621B1 (fr) 2015-10-21
EP2604285A1 (fr) 2013-06-19
DK2604286T3 (en) 2014-12-08
JP2016130246A (ja) 2016-07-21
WO2005001023A3 (fr) 2005-04-28
PT2604285E (pt) 2014-11-12
EP1625149A2 (fr) 2006-02-15
EP3381515A1 (fr) 2018-10-03
EP1625149B1 (fr) 2016-02-17
EP2604287B1 (fr) 2016-12-07
DK1625149T3 (en) 2016-05-30
ES2694574T3 (es) 2018-12-21
ES2520815T3 (es) 2014-11-11
ZA200509229B (en) 2007-03-28
KR101161823B1 (ko) 2012-07-03
KR20060008950A (ko) 2006-01-27
EP2604285B1 (fr) 2014-08-27
US20220372172A1 (en) 2022-11-24
US8148322B2 (en) 2012-04-03
JP6698756B2 (ja) 2020-05-27
JP5650040B2 (ja) 2015-01-07
DK2604621T3 (en) 2016-02-01

Similar Documents

Publication Publication Date Title
HK1231424A1 (zh) 將分子遞送到細胞的方法和載體複合物
GB0710730D0 (en) System and method to support single instance storage operations
EP1718602A4 (fr) Molecules porteuses et therapeutiques
EP1552002A4 (fr) Molecules toxine-aptamere et procedes d'utilisation correspondants
ZA200600716B (en) Improvements in and to processes
GB2398408B (en) Improvements in and relating to data handling apparatus and methods
EP1789855A4 (fr) Systeme servant a maintenir la purete de l'hydrogene dans des generateurs electriques et procedes associes
GB2407272B (en) Improvements in and relating to peripheral neurostimulation
HK1090451A1 (en) System and method for direct deposit using lockingcache
AU2003291676A8 (en) Textiles for use in bioreactors
EP1560948A4 (fr) Procede d'electrolyse et cellule utilisee dans celui-ci
GB0508065D0 (en) Cell culture carriers
GB0700288D0 (en) Improvements in and relating to supporting apparatus
GB0410999D0 (en) Method and aparatus for electrode dressing
GB0505643D0 (en) Improvements in and relating to neurostimulation
EP1470214A4 (fr) Sake infuse et procede de fabrication correspondant
AU2003225461A8 (en) Composition and method for supporting cancer treatments
GB0426903D0 (en) Complexes and methods
EP1820339A4 (fr) Terminal de decodage de contenus de diffusion multimedia numeriques a grande vitesse et procede associe
EP1596815A4 (fr) Composition et technique destinees a inhiber la survie cellulaire
GB0208364D0 (en) Improvements in and relating to methods and apparatus for genotyping
GB2402060B (en) Improvements in and relating to support apparatus
IL165453A0 (en) Methods for reducing boron concentration in high salinity liquid
GB0214902D0 (en) Methods for cell culture
GB0319804D0 (en) Cell culture method

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240502